Items Tagged ‘Recurrent Bladder Cancer’

March 30th, 2015

Votrient® plus Taxol® Promising in Relapsed and Refractory Bladder Cancer

By

The treatment combination of Votrient® (pazopanib) plus Taxol® (paclitaxel) appears active against bladder cancer that has not responded to or come back after previous therapy. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the […]

View full entry

Tags: Bladder Cancer, News, paclitaxel, pazopanib, Phase II study, Recurrent Bladder Cancer, Stages II-III Bladder Cancer, Taxol, Votrient


March 16th, 2015

Cyramza® plus Taxotere® Promising in Advanced Bladder Cancer

By

The treatment combination of Cyramza® (ramucirumab) plus Taxotere® (docetaxel) appears to extend progression-free survival in patients with advanced bladder cancer that has relapse after previous treatment. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in […]

View full entry

Tags: Bladder Cancer, cyramza, News, Recurrent Bladder Cancer, Stage IV/Metastatic Bladder Cancer, taxotere


June 23rd, 2014

Survival Benefit with Immediate Adjuvant Chemotherapy in Invasive Bladder Cancer

By

Results from a recent Phase III clinical trial suggest that patients with invasive bladder cancer may benefit from treatment with immediate adjuvant chemotherapy. These finding were presented at the 2014 American Society of Clinical Oncology (ASCO) meeting held in Chicago, May 31–June 3. Patients with Stage III, or invasive, bladder cancer have cancer that invades […]

View full entry

Tags: Bladder Cancer, News, Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV/Metastatic Bladder Cancer, Stages II-III Bladder Cancer, surgery


June 12th, 2014

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer

By

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1 positive metastatic bladder cancer. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the United States. Bladder cancer is the […]

View full entry

Tags: Bladder Cancer, MPDL3280A, News, PD-L1, Recurrent Bladder Cancer, Stage IV/Metastatic Bladder Cancer


January 24th, 2013

Robotic Bladder Cancer Surgery Safe and Effective

By

Robotic-assisted surgery for invasive bladder cancer is effective and results in less bleeding and shorter hospital stays when compared to the traditional open procedure, according to the results of a study published in the Journal of Urology. The bladder is a hollow organ located in the pelvis. Its primary function is to store urine. The bladder […]

View full entry

Tags: Bladder Cancer, News, Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV/Metastatic Bladder Cancer, Stages 0-I Bladder Cancer, Stages II-III Bladder Cancer


March 9th, 2010

Cystoscopy Alone Is the Most Cost-effective Way to Monitor for Recurrence of Bladder Cancer

By

The addition of a urine test to standard cystoscopy screening in order to monitor for bladder cancer recurrence unnecessarily increases the cost of monitoring as well as the risk for a false-positive result and does not improve tumor detection, according to the results of a study presented at the 2010 Genitourinary Cancers Symposium in San […]

View full entry

Tags: Bladder Cancer, News, Recurrent Bladder Cancer